{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-001254","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.963440+00:00","generated_at":"2026-06-18T22:56:22.143196+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Celldex Q4 net loss $26.5M ($0.56/sh); barzolvolimab Phase 2 CSU enrollment to complete by Q3 2023","bullets":["Net loss of $26.5M ($0.56 per share) for Q4 2022; full year net loss $112.3M ($2.40 per share).","Cash, cash equivalents and marketable securities at Dec 31, 2022: $305.0M, down from $323.5M at Sep 30, 2022.","Revenue $1.6M in Q4 2022, $2.4M for full year; R&D expenses $22.9M in Q4, $82.3M for full year.","Barzolvolimab Phase 2 CSU enrollment expected to complete by Q3 2023; topline data late 2023 or Q1 2024.","Rita Jain, M.D. appointed to Board of Directors; Phase 2 EoE study initiation expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-001254","json":"https://secwatch.observer/filing/0001171843-23-001254.json","markdown":"https://secwatch.observer/filing/0001171843-23-001254.md","text":"https://secwatch.observer/filing/0001171843-23-001254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184323001254/0001171843-23-001254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184323001254/f8k_022823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:56:22.143196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"301459796408cafd3507f2bf6fe6416307255766","claim":"Celldex Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744218/000117184323001254/0001171843-23-001254-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}